83% of all CD8+ T cells were in direct contact with tumor cells after 7 d of solitomab treatment compared with 24% in EpCAM antibody–treated controls (P < 0.01, Student’s t test; Fig. 4 I and Video 2). Here, EPCAM is linked to neoplasm.